CRISPR Therapeutics AG (CRSP) Prepaid Assets (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Prepaid Assets of $6.6 million for Q1 2026, down 33.18% sequentially from $9.8 million in Q4 2025, and down 46.64% YoY from $12.3 million in Q1 2025.
CRISPR Therapeutics AG (CRSP) Prepaid Assets (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Prepaid Assets for 12 years, with the latest figure at $6.6 million in Q1 2026.
- Quarterly Prepaid Assets fell 46.64% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (down 46.64% YoY) and the FY2025 annual result came in at $9.8 million, up 18.5% from the prior year.
- Prepaid Assets fell to $6.6 million in Q1 2026 per CRSP's latest filing, from $9.8 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $41.7 million in Q2 2022 and troughed at $6.6 million in Q1 2026.
- A 5-year average of $19.3 million and a median of $13.4 million in 2025 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2023 and 2025: Prepaid Assets plunged 61.85% in 2023, then surged 62.28% in 2025.
- Over 5 years, Prepaid Assets stood at $37.7 million in 2022, then slumped by 61.85% to $14.4 million in 2023, then tumbled by 42.26% to $8.3 million in 2024, then grew by 18.5% to $9.8 million in 2025, then slumped by 33.18% to $6.6 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $6.6 million, $9.8 million, and $13.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.42 Mn |
| Mar 31, 2026 | 6.58 Mn |
| Dec 31, 2025 | 9.84 Mn |
| Sep 30, 2025 | 13.38 Mn |
| Jun 30, 2025 | 12.43 Mn |
| Mar 31, 2025 | 12.33 Mn |
| Dec 31, 2024 | 8.31 Mn |
| Sep 30, 2024 | 8.25 Mn |
| Jun 30, 2024 | 8.79 Mn |
| Mar 31, 2024 | 11.50 Mn |
| Dec 31, 2023 | 14.39 Mn |
| Sep 30, 2023 | 20.76 Mn |
| Jun 30, 2023 | 21.47 Mn |
| Mar 31, 2023 | 24.80 Mn |
| Dec 31, 2022 | 37.71 Mn |
| Sep 30, 2022 | 36.68 Mn |
| Jun 30, 2022 | 41.65 Mn |
| Mar 31, 2022 | 39.21 Mn |
| Dec 31, 2021 | 38.08 Mn |
| Sep 30, 2021 | 41.42 Mn |